Roche alerts doctors to first case of fatal anaphylaxis with Actemra
This article was originally published in Scrip
Executive Summary
Roche has alerted physicians globally to a post-marketing report of the first reported case of fatal anaphylaxis in a patient with rheumatoid arthritis (RA) treated with its first-in-class IL-6-receptor inhibiting monoclonal antibody, Actemra/RoActemra (tocilizumab) – a 67-year woman who received her fifth infusion.